Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.
Krystal Biotech, Inc. Common Stock (KRYS) has a market cap of $7.95B with year-over-year revenue growth of +33.9%. Net margin stands at 52.6%. The stock trades at a P/E ratio of 38.8.
Compared to other companies in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector, KRYS posted revenue growth of +33.9% and trades at a P/E of 38.8.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.